Novo Nordisk shares take a hit after a report revealed Eli Lilly’s better weight loss drug

Shares were down 1.1% after JAMA published an analysis showing patients on Mounjaro lost more weight, faster.

Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly’s own treatment Mounjaro leads to faster and greater weight loss.